- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01158235
A Phase I/IIa Study to Evaluate the Safety, Tolerability and Efficacy of Topical LTX-109 in Subjects Nasally Colonized With Methicillin-resistant/-Sensitive Staphylococcus Aureus (MRSA/MSSA)
A Randomised, Double-blind, Placebo-controlled, Ascending Dose Phase I/IIa Study to Evaluate the Safety, Tolerability and Efficacy of Topical LTX-109 in Subjects Nasally Colonized With Methicillin-resistant/-Sensitive Staphylococcus Aureus (MRSA/MSSA)
This is a pilot study conducted to evaluate the safety, local tolerability and efficacy of LTX-109(Lytixar™), a lytic peptide designed to kill bacterias quickly and efficient. LTX-109 (Lytixar™)will be applied in the anterior nares in subjects who are carriers of nasal colonies of MRSA/MSSA.
The extent of systemic absorption of LTX -109 when applied to the anterior nares will be evaluated and the effect of Lytixar™ as to clear colonies of MRSA/MSSA during the the observation period and Week 2 to Week 9 after treatment.
Study Overview
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Malmö, Sweden, 205 02
- Skane University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female subjects between the ages of 16 and 75, inclusive.
- Female subjects must be non-pregnant, non-lactating.
- Female subjects of child bearing potential and male subjects with female partners of child-bearing potential must use an adequate form of diaphragm or condom with spermicidal prior to entry into the study and two weeks following the completion of all follow-up procedures 9 weeks after treatment. Hormone contraception or hormonal IUDs alone are not acceptable contraception
- Signed and dated written informed consent by subject.
- Subject's medical condition is stable, with no clinically significant abnormalities.
- Subject's pre-study laboratory screen of haematology, clinical chemistry and urinalysis are normal or if abnormal, not considered clinically significant.
- Subjects must be able to understand the subject information and the consent form, and be willing to return to the study site for follow up visits, comply with requirements, instructions and restrictions of the study listed in the informed consent form.
- All family members, to a subject carrying MRSA (not applicable for MSSA positive) should also be screened for MRSA. Subjects that are eligible may be included in the study, and family members not eligible or willing to participate should be offered treatment for decolonization of MRSA according to standard treatment and investigators choice.
Exclusion Criteria:
- Negative nasal culture for MRSA/MSSA on the first screen visit.
- Negative nasal cultures for MRSA/MSSA at any occasion during the run-in period day -14 to -3 day prior to Baseline.
- Severe eczema (eczema infected with MRSA) or skin wounds, clinically significant according to investigator.
- Previous or concurrent treatment with antimicrobials for an infection within the last 28 days prior to baseline.
- MRSA decolonization attempt in the previous 6 months (prior treatment for a MRSA infection is not an exclusion criterion).
- Systolic BP is ≥170 mmHg, or diastolic BP is ≥100 mmHg or HR is ≥110 bpm.
- Inability to take medications nasally.
- Evidence of active rhinitis, sinusitis, or upper respiratory infection.
- Disease in the region of the application sites, significant history of trauma or skin disease in the region of the application sites, current nasal skin or nasal septum condition requiring treatment or nasal surgery in the previous 3 months.
- Significant ongoing or history of drug or alcohol abuse in the opinion of the investigator makes the subject unsuitable for enrolment.
- Use of prescription or non prescription drugs within minimum 7 days prior to the first dose of study medication. Subjects on stable doses of non-prescription painkillers, anti-inflammatory drugs (such as paracetamol and NSAIDs), oral antidiabetics or insulin may be allowed to be included to the study at the discretion of the investigator.
- Known allergic reactions or hypersensitivity of significant severity in general and specifically to any component of the study medication.
- Systemic illness requiring treatment within 28 days prior to baseline.
- Clinically significant illness (defined by the investigator) in the past 4 weeks before the Screening visit.
- Current or history of significant hepatic, renal, endocrine, cardiac, nervous, psychiatric, gastrointestinal, pulmonary, haematological, or metabolic disorder that is not in a stable condition. Malignancy <5 years since final treatment.
- Current or history of any significant disease or condition known to interfere with the absorption, distribution, metabolism or excretion of drugs.
- Known positive test for Human Immunodeficiency Virus (HIV) antibody, hepatitis B virus surface antigen or hepatitis C virus antibody.
- Other unspecified reasons that, in the opinion of the investigator make the subject unsuitable for enrolment.
- Treatment with an investigational drug within 30 days prior to the first dose of study medication.
Study Plan
How is the study designed?
Design Details
- Allocation: RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: LTX-109 (Lytixar)
Ascending dose study.
Start enrollment to group 1: 1% LTX-109/placebo, then group 2: 2%LTX-109/placebo and finally group 3: 5%LTX-109/placebo dosed in each nostril TID for 3 consecutive days.
|
1%, 2% and 3% Lytixar (gel formulation).
TID for 3 days.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Local tolerability in the anterior nares
Time Frame: Day 1, 2, 3. week 2-9 after final treatment.
|
To explore safety, local tolerability and efficacy of LTX-109 when applied topically into the anterior nares in subjects with nasal colonisation of MRSA/MSSA.
To determine the extent of systemic absorption of LTX -109 when applied to the anterior nares.
|
Day 1, 2, 3. week 2-9 after final treatment.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To evaluate recurrence of MRSA/MSSA during the observation period.
Time Frame: Week 2 to Week 9 after treatment.
|
Week 2 to Week 9 after treatment.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Anna Nilsson, MD, PhD, Skåne University Hospital, Malmö
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- C10-109-02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nasal Carriers MRSA
-
University of British ColumbiaUnknownNasal Colonization With MRSA BacteriaCanada
-
Northwestern UniversityCompletedNasal Carriers of Staphylococcus AureusUnited States
-
Hvidovre University HospitalRecruiting
-
University of California, San FranciscoThe Bluefield Project to Cure Frontotemporal DementiaCompletedProgranulin Mutation CarriersUnited States
-
Indiana UniversityWithdrawnHospital Acquired MRSA | Community Acquired MRSAUnited States
-
Leiden University Medical CenterRecruiting
-
Indiana UniversityUnknown
-
Johns Hopkins UniversityRobert Wood Johnson FoundationCompleted
-
University of GuelphMcMaster UniversityRecruitingAutosomal Recessive Disorder (Genetic Carriers of PKU)Canada
Clinical Trials on LTX-109
-
Lytix Biopharma ASCompletedAtopic Dermatitis | Gram-positive, Skin Infections | Mild Eczema/DermatosesHungary
-
Lytix Biopharma ASCompletedNon-bullous ImpetigoDominican Republic
-
Pharma Holdings ASUniversity Hospital of North NorwayCompleted
-
Pharma Holdings ASCTC Clinical Trial Consultants ABCompletedA Study to Evaluate the Safety and Efficacy of 3% LTX-109 for Nasal Decolonisation of StaphylococcusNasal Decolonization of Staphylococcus AureusSweden
-
Pharma Holdings ASCTC Clinical Trial Consultants ABCompletedNasal Decolonization of Staphylococcus AureusSweden
-
Pharma Holdings ASCTC Clinical Trial Consultants ABRecruiting
-
C. R. BardCompletedFemoral Artery Occlusion | Femoral Artery Stenosis | Stenosis of Popliteal Arteries | Occlusion of Popliteal ArteriesChina
-
Verrica Pharmaceuticals Inc.Instat Clinical Research; HeartcoR Solutions; Myonex; Vial Health Technology, IncRecruitingCarcinoma | Skin Cancer | Basal Cell Carcinoma | Cancer of the Skin, Basal Cell | Cancer of the SkinUnited States
-
Lytix Biopharma ASKarolinska University Hospital; Oslo University HospitalCompletedCancer With Transdermal Accessible TumourSweden, Norway
-
Lytix Biopharma ASHerlev HospitalCompletedSoft Tissue SarcomaDenmark